Login to Your Account

Other news to note

Wednesday, February 14, 2018

Wuxi Biologics, of Shanghai, said partner Tychan Pte Ltd., of Singapore, dosed the first patient with Zika antibody tyzivumab in a phase Ia trial in Singapore. Tyzivumab is directed against a specific quaternary epitope of the envelope (E) protein on the surface of the virus, limiting viral fusion to host cells and preventing viral replication.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription